Our cohort policies for approved drugs can be found below (further policies will added once they are approved).
Abiraterone + Cabazitaxel for Prostate Cancer - Abiraterone and Cabazitaxel were originally approved by the CDF panel for funding. In June 2012, Abiraterone received approval from the National Institute for Health and Clinical Excellence (NICE). This means it will no longer come under the remit of the Cancer Drugs Fund. The full NICE guidance is available here. The WM CDF will continue to fund the use of Abiraterone in line with the CDF policy for three months from the publication of the NICE Technology Appraisal; the appropriate PCT is expected to provide funding for Abiraterone, in line with NICE recommendations, from 27 September 2012. An amended policy for Cabazitaxel is available below.
Sequential use of abiraterone or cabazitaxel, after prior docetaxel treatment and cabazitaxel or abiraterone for prostate cancer
Abraxane (Paclitaxel albumin) for Breast Cancer
Alemtuzumab for B-cell Chronic Lymphocytic Leukaemia (CLL)
Azacitidine in Chronic Myelomonocytic Leukaemia 2, with myeloproliferative disorder
Azacitidine for Myelodysplastic Syndrome - This drug was originally approved for funding by the ICDF panel in October 2010. It has since received approval from the National Institute of Health and Clinical Excellence (NICE) , so will no longer come under the remit of the Cancer Drug Fund. The relevant NICE guidance is available here. The WM CDF continued to fund the use of Azacitadine in line with the CDF policy for three months from the publication of the NICE Technology Appraisal; the appropriate PCT is expected to provide funding for Azacitadine, in line with NICE recommendations, from 1 July 2011.
Bendamustine in CLL - This drug was originally approved for funding by the ICDF panel in November 2010. It has since received approval from the National Institute of Health and Clinical Excellence (NICE) , so will no longer come under the remit of the Cancer Drug Fund. The relevant NICE guidance is available here. The WM CDF will continue to fund the use of Bendamustine in CLL in line with the CDF policy for 3 months from the publication of the NICE Technology Appraisal; the appropriate PCT will be expected to provide funding for Bendamustine, in line with NICE recommendations, from 1 June 2011.
Bendamustine monotherapy or combined with Rituximab for relapsed CLL
Bendamustine + Rituximab for 1st Line CLL
Bendamustine for Indolent non-Hodgkin’s lymphoma (as monotherapy following Rituximab)
Bevacizumab for Advanced Breast Cancer
Bevacizumab for Advanced Colorectal Cancer
Bevacizumab for Ovarian Cancer
Bortezomib for Multiple Myeloma with renal failure
Cabazitaxel for Prostate Cancer
Capecitabine (with GEM) for Pancreatic Cancer
Cetuximab + Panitumumab for Advanced Colorectal Cancer
Cetuximab for recurrent and/or metastatic Squamous Cell Carcinoma of the head and neck
Eribulin for Advanced Breast Cancer
Everolimus for Neuroendocrine Tumours
Everolimus for Renal Cell Cancer
Everolimus in combination with exemestane for breast cancer
FOLFOX for Pancreatic Cancer
FOLFIRINOX for inoperable Pancreatic Cancer
Fulvestrant for Advanced Breast Cancer
Imatinib adjuvant for Gastrointestinal Stromal Tumour (GIST)
Imatinib for Locally Advanced or Metastatic Chordoma
Imatinib for Melanoma
Imatinib for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia (Ph+ALL)
Ipilimumab for Melanoma This drug was originally approved for funding by the WM Cancer Drugs Fund panel. It has since received approval from the National Institute of Health and Clinical Excellence (NICE) , so will no longer come under the remit of the Cancer Drug Fund. The relevant NICE guidance is available here:
The WM CDF will continue to fund the use of ipilimumab/ vemurafenib in line with the CDF policy for 3 months from the publication of the NICE Technology Appraisal; the appropriate Responsible Commissioner is expected to provide funding from 1st April 2013, in line with NICE recommendations.
Lapatinib for Advanced Breast Cancer
Lenalidomide for Multiple Myeloma
Lenalidomide for Myelodysplasia
Ofatumumab for Chronic Lymphocytic Leukaemia (CLL)
Pazopanib for Renal Cancer - This drug was originally approved for funding by the ICDF panel. It has since received approval from the National Institute of Health and Clinical Excellence (NICE) , so will no longer come under the remit of the Cancer Drug Fund. The relevant NICE guidance is available here. The WM CDF continued to fund the use of Pazopanib for renal cancer in line with the CDF policy for 3 months from the publication of the NICE Technology Appraisal; the appropriate PCT is expected to provide funding for Pazopanib for renal cancer, in line with NICE recommendations.
Pemetrexed Maintenance for Non-Squamous Non-Small Cell Lung Cancer
Rituximab for Follicular Lymphoma - This drug was originally approved for funding by the ICDF panel in December 2010. It has since received approval from the National Institute of Health and Clinical Excellence (NICE) , so will no longer come under the remit of the Cancer Drug Fund. The relevant NICE guidance is available here. The WM CDF will continue to fund the use of Rituximab in line with the CDF policy for 3 months from the publication of the NICE Technology Appraisal; the appropriate PCT will be expected to provide funding for Rituximab, in line with NICE recommendations, from 1 October 2011.
Rituximab for Various CD20 Positive Lymphomas
Rituximab + Chemotherapy for 1st Line Mantle Cell Lymphoma
Sorafenib for Hepatocellular Cancer
Sunitinib + Everolimus for Pancreatic Neuroendocrine Tumours
Temsirolimus for Renal Carcinoma
Trastuzumab for Gastric Cancer
Vemurafenib for Melanoma
Vinorelbine HER2 for breast cancer
The following drugs were not approved for funding:
Azacitidine in Chronic Myelomonocytic Leukaemia
Bendamustine for Multiple Myeloma
Bevacizumab for Recurrent High Grade Glioma
Cetuximab for Advanced Colorectal Cancer
Ruxolitinib for the treatment of disease related splenomegaly
Vinflunine for Transitional Cell Carcinoma of the Urothelium
Yttrium for Neuroendocrine Tumours
The application process for the West Midlands Cancer Drug Fund is explained here.
If you have any general queries regarding the process you can either email wm.cancerdrugs@nhs.net or call Janice Cunningham at West Midlands Strategic Commissioning Team (WMSCT) offices on telephone number: 0121 695 2374.